Skip to content
Dipna Pharmachem logo

Dipna Pharmachem

543594 BSE
₹3.99

Close ·

P/E
5.70
View as Markdown
MCP
Close 4 Nov 2026 ₹3.99 −15.17 −79.2% 1Y
Start ₹19.16

Key Fundamentals

SMEPharmaceuticals & BiotechnologyHealthcare

Price-based figures at the close · TTM

ROCE
7.64%
Debt to Equity
0.21
EPS (TTM)
₹0.70
Book Value
₹23.70
Market Cap
—
P/E (TTM)
5.70
P/B
0.17
ROE
5.22%
Dividend Yield
0.00%
EBITDA
₹4.99 Cr
52W High
₹19.92
52W Low
₹3.62

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

42 Weak

Data confidence 100/100

Category scores

Quality
31
Poor
Returns, margins, earnings quality 22% weight
Valuation
66
Good
Cheap vs sector & own history 24% weight
Growth
43
Weak
Sales & profit trajectory 9% weight
Financial Health
37
Poor
Solvency, leverage, coverage 9% weight
Momentum
3
Poor
Trend strength, vol-adjusted 12% weight
Ownership
50
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Company has reduced debt.
  • Stock is trading at 0.17 times its book value
  • Company's working capital requirements have reduced from 91.1 days to 55.6 days

Weaknesses

4
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Promoter holding is low: 9.13%
  • Company has a low return on equity of 3.93% over last 3 years.
  • Promoter holding has decreased over last 3 years: -48.1%

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBearish865
OscillatorsBullish162
Moving AveragesStrong Bearish703

Key readings

RSI (14)
45.26
Neutral
MACD (12,26,9)
−0.18
Bullish
SMA (50)
4.57
Bearish
SMA (200)
7.88
Bearish

As of

Growth Rate

From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025.

Revenue

Revenue growth by window
5Y+33.00%
3Y+8.86%
1Y+3.20%

Net profit

Net profit growth by window
5YZero base
3Y+44.22%
1Y+200.00%

Operating cash flow

Operating cash flow growth by window
5YOutflow widened by ₹16 Cr
3YOutflow narrowed by ₹3 Cr
1YOutflow widened by ₹9 Cr

Operating margin· change in pp

Operating margin growth by window
5Y+3.88 pp
3Y+1.88 pp
1Y+0.68 pp

Trailing twelve months: Results are not reported for each of the last eight quarters, so there is no trailing-twelve-month figure.

Revenue by year

Revenue by year, ₹ crore
Mar 2018₹17.00 Cr
Mar 2019₹20.00 Cr
Mar 2020₹30.00 Cr
Mar 2021₹31.00 Cr
Mar 2022₹73.00 Cr
Mar 2023₹100 Cr
Mar 2024₹164 Cr
Mar 2025₹125 Cr
Mar 2026₹129 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2018₹0.00 Cr
Mar 2019₹0.00 Cr
Mar 2020₹0.00 Cr
Mar 2021₹0.00 Cr
Mar 2022₹1.00 Cr
Mar 2023₹1.00 Cr
Mar 2024₹1.00 Cr
Mar 2025₹1.00 Cr
Mar 2026₹3.00 Cr

Quarterly Results

₹ Cr

Results for the period ended Jun 2026 were due by 14 Aug 2026 and are not in this table yet.

543594 quarterly results, ₹ crore
Particulars Mar 2025Dec 2025Mar 2026
Sales
15.92
53.52
2.05
Expenses
14.64
51.87
1.59
Operating Profit
1.28
1.65
0.46
OPM %
8.04%
3.08%
22.44%
Other Income
0
0
0
Interest
0.6
0.23
0.23
Depreciation
0
0
0
PBT
0.68
1.42
0.23
Tax %
26.47%
26.06%
21.74%
Net Profit
0.5
1.04
0.18
EPS (₹)
0.21
0.4
0.07

Profit & Loss

₹ Cr
543594 profit and loss, annual, ₹ crore
Particulars Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
17
20
30
31
73
100
164
125
129
Expenses
16
20
30
31
71
98
161
121
124
Operating Profit
0
0
0
0
2
2
3
4
5
OPM %
2.4%
2.4%
1.5%
1.3%
3%
2.4%
2.1%
3%
3.9%
Other Income
0
0
0
0
0
0
0
0
0
Interest
0
0
0
0
1
1
2
2
1
Depreciation
0
0
0
0
0
0
0
0
0
PBT
0
0
0
0
2
1
1
1
4
Tax %
14%
40%
0%
60%
26%
34%
24%
32%
26%
Net Profit
0
0
0
0
1
1
1
1
3
EPS (₹)
1.2
0.6
1.2
0.4
23.4
0.37
0.45
0.4
1
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%

Balance Sheet

₹ Cr
543594 balance sheet, annual, ₹ crore
Particulars Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
0.04
0.04
0.04
0.04
0.04
12
24
24
26
Reserves
0
0
1
1
2
12
13
14
36
Borrowings
5
6
10
12
10
16
19
17
13
Other Liabilities
6
8
8
12
24
37
76
77
130
Total Liabilities
11
14
18
25
36
78
133
132
206
Fixed Assets
0
0
0
0
0
0
0
0
0
CWIP
0
0
0
0
0
0
0
0
0
Investments
0
0
0
0
0
0
0
0
0
Other Assets
11
14
18
25
36
78
133
132
206
Total Assets
11
14
18
25
36
78
133
132
206

Cash Flow

₹ Cr
543594 cash flow, annual, ₹ crore
Particulars Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
—
—
−3
−2
3
−21
−5
−9
−18
Investing
—
—
0
0
0
0
0
0
0
Financing
—
—
3
2
−3
26
14
−4
19
Net Cash Flow
—
—
0
0
0
5
8
−13
0
Free Cash Flow
—
—
−3
−2
3
−21
−5
−9
−18
CFO/EBITDA
—
—
−693
−618
148
−893
−157
−246
−347

Ratios

543594 financial ratios, annual
Particulars Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
132
160
134
176
135
104
69
135
136
Inventory Days
112
66
70
89
34
72
86
88
144
Days Payable
142
148
105
145
123
139
172
243
375
Cash Conversion Cycle
103
78
99
120
46
38
−17
−20
−95
Working Capital Days
3
6
44
47
37
108
80
137
56
ROCE %
—
8%
5%
3%
17%
9%
7%
7%
8%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Dipna Pharmachem insights

55 extracted metrics across FY18–FY26.

Shareholding Pattern

As of Sep 2026

  • Public 82.70%
  • Promoters 9.13%
  • Others 8.18%

No promoter shares pledged as of 14 Oct 2026

Change since Jun 2026

Documents

Frequently Asked Questions about Dipna Pharmachem

What does Dipna Pharmachem Ltd do?
Incorporated in 2011, Dipna Pharmachem Ltd is in the business of Pharmaceutical Trading
Where is Dipna Pharmachem Ltd (DPL) listed?
Dipna Pharmachem Ltd trades under code 543594 on the BSE.
Which sector does Dipna Pharmachem Ltd belong to?
Dipna Pharmachem Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Dipna Pharmachem Ltd?
Dipna Pharmachem Ltd trades at a PE ratio of 5.70 as of 4 Nov 2026, on earnings per share of ₹0.7, against a book value of ₹23.7 per share.
What is the 52-week high and low of Dipna Pharmachem Ltd?
Over the last 52 weeks Dipna Pharmachem Ltd has traded between ₹3.62 and ₹19.92 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Dipna Pharmachem Ltd?
Dipna Pharmachem Ltd reported a return on equity of 5.22%. Its debt-to-equity ratio is 0.21.

Company Information

Incorporated in 2011, Dipna Pharmachem Ltd is in the business of Pharmaceutical Trading

Website dipnapharmachem.com
Listed 8 Sep 2022
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/543594.md for Dipna Pharmachem Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month